Vera Therapeutics Inc

VERA exhibits a medium-term Stage 2 advancing structure with clear higher highs and higher lows, trading near its rising 9- and 20-day EMAs but below the 50-day and 200-day SMAs. Short-term momentum is neutral as price consolidates around the EMAs without exhaustion, suggesting patience while watching for pullback acceptance into the 9/20 EMA zone. Long-term downtrend remains intact given price below the declining 200-day SMA, posing overhead resistance.

• ↑FDA accelerated approval of TRUTAKNA enables imminent commercialization.
• ↑Strong momentum factors underpin recent upward stock trend.
• ↓Q2 net loss widened to $109.5 M from $76.5 M YoY.